Results 81 to 90 of about 12,163 (157)

Immunogenicity and protective efficacy of a multi-antigenic adenovirus-based vaccine candidate against Mycobacterium tuberculosis

Frontiers in Microbiology
IntroductionThe inadequate efficacy of the Bacillus Calmette–Guérin (BCG) vaccine against adult pulmonary tuberculosis (TB) necessitates the development of new and effective vaccines. Human adenovirus serotype 5 (Ad5), which induces T-cell response, is a
Jin-Seung Yun, Jin-Seung Yun, Eunkyung Shin, Young-Ran Lee, Jung-Ah Lee, Hyeokjin Lee, Jong-Seok Kim, Sung Jae Shin, Sang-Jun Ha, Sang-Won Lee, Dokeun Kim, Jung-Sik Yoo, Hye-Sook Jeong   +12 more
doaj   +1 more source

Efficacy and immunogenicity of rKVAC85B in a BCG prime-boost regimen against H37Rv and HN878 Mycobacterium tuberculosis strains.

PLoS ONE
Mycobacterium tuberculosis infection accounted for 1.3 million deaths worldwide in 2022. Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB); however, it has limited protective efficacy in adults.
Eunkyung Shin, Jin-Seung Yun, Young-Ran Lee, Hye-Ran Cha, Soo-Min Kim, Sung-Jae Shin, Sang-Won Lee, Gyung Tae Chung, Dokeun Kim, Jung Sik Yoo, Jong-Seok Kim, Hye-Sook Jeong   +11 more
doaj   +1 more source

Screening and preclinical assessment of novel Mycobacterium tuberculosis recombinant antigens based tuberculin skin testing

Frontiers in Immunology
IntroductionA new class of Mycobacterium tuberculosis (MTB) antigen-based skin tests was recommended by WHO for the diagnosis of TB infection. However, their performance in some settings remains suboptimal.
Xichao Ou, Xichao Ou, Eryong Liu, Eryong Liu, Faiqa Rashid, Shaojun Pei, Shaojun Pei, Shaojun Pei, Guoqin Zhang, Richard Anthony, Ruida Xing, Ruida Xing, Fei Huang, Fei Huang, Hui Xia, Hui Xia, Yang Zheng, Yang Zheng, Yuanyuan Song, Yuanyuan Song, Yang Zhou, Yang Zhou, Bing Zhao, Bing Zhao, Shengfen Wang, Shengfen Wang, Minggui Lin, Lin Zhou, Lin Zhou, Yanlin Zhao, Yanlin Zhao   +30 more
doaj   +1 more source

Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter? [PDF]

Journal of Ancient Diseases & Preventive Remedies, 2014
Bacillus Calmette-Guerin (BCG) is the common name given to a family of vaccines against human tuberculosis. Created in 1921 by the in vitro attenuation of a virulent Mycobacterium bovis in France, the BCG vaccine continues to generate debate and confusion after nearly a century of use.
openaire   +1 more source

Protection Induced by Simultaneous Subcutaneous and Endobronchial Vaccination with BCG/BCG and BCG/Adenovirus Expressing Antigen 85A against Mycobacterium bovis in Cattle.

PLoS ONE, 2015
The incidence of bovine tuberculosis (bTB) in the GB has been increasing since the 1980s. Immunisation, alongside current control measures, has been proposed as a sustainable measure to control bTB. Immunisation with Mycobacterium bovis bacillus Calmette-
Gillian S Dean, Derek Clifford, Adam O Whelan, Elma Z Tchilian, Peter C L Beverley, Francisco J Salguero, Zhou Xing, Hans M Vordermeier, Bernardo Villarreal-Ramos   +8 more
doaj   +1 more source

Boosting BCG with recombinant influenza A virus tuberculosis vaccines increases pulmonary T cell responses but not protection against Mycobacterium tuberculosis infection

PLoS ONE, 2021
The current Mycobacterium bovis BCG vaccine provides inconsistent protection against pulmonary infection with Mycobacterium tuberculosis. Immunity induced by subcutaneous immunization with BCG wanes and does not promote early recruitment of T cell to the
Heni Muflihah, Manuela Flórido, Leon C. W. Lin, Yingju Xia, James A. Triccas, John Stambas, Warwick J. Britton   +6 more
doaj  

Immunogenicity and Protective Efficacy against Murine Tuberculosis of a Prime-Boost Regimen with BCG and a DNA Vaccine Expressing ESAT-6 and Ag85A Fusion Protein

Clinical and Developmental Immunology, 2011
Heterologous prime-boost regimens utilizing BCG as a prime vaccine probably represent the best hope for the development of novel tuberculosis (TB) vaccines.
Jia Lu, Chun Wang, Zhiguang Zhou, Ying Zhang, Tingting Cao, Chunwei Shi, Zhenhua Chen, Lingxia Chen, Changxue Cai, Xionglin Fan   +9 more
doaj   +1 more source

Study on recombinant BCG to prevent infections of intracellular pathogens.

Japanese journal of leprosy, 2000
Studies on recombinant BCG (rBCG) which my group carried out so far were reviewed. Recombinant BCG which secreted alpha antigen-fused foreign antigen was constructed and tested for its ability to induce protective immunity. Thus, rBCG secreting merozoite surface protein 1 (MSP1) of Plasmodium yoelii efficiently protected the infection more than ...
openaire   +2 more sources

Unleashing the power of the BCG vaccine in modulating viral immunity through heterologous protection: A scoping review

Human Vaccines & Immunotherapeutics
The Bacillus Calmette-Guérin (BCG) vaccine, used against tuberculosis for a century, shows promise in protecting against viral infections through trained/innate immunity.
Thales A. Campelo, Natália S. Oliveira, Pedro F. N. Souza, Denis F. G. de-Oliveira, Cristiane C. Frota, Paulo R. Z. Antas   +5 more
doaj   +1 more source

Characterization of the humoral and cellular immunity induced by a recombinant BCG vaccine for the respiratory syncytial virus in healthy adults. [PDF]

Front Immunol, 2023
Pacheco GA, Andrade CA, Gálvez NMS, Vázquez Y, Rodríguez-Guilarte L, Abarca K, González PA, Bueno SM, Kalergis AM.   +8 more
europepmc   +1 more source